SCHEMBL6099154

SCHEMBL6099154

Cc1ccc(S(=O)(=O)n2cc(C3=CC(=O)NC3=O)c3cc(OCc4ccccc4)ccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.52
L3MBTL1 Q9Y468 1/20 0.44
DRD2 P14416 4/20 0.43
HTR7 P34969 3/20 0.43
MAOA P21397 3/20 0.43
MAOB P27338 3/20 0.43
HTR2A P28223 4/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
AR P10275 1/20 0.41
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP7 P09237 1/20 0.40
MMP9 P14780 1/20 0.40
MMP12 P39900 1/20 0.40
MMP14 P50281 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6099113 0.89 HTR6 (0.50) HTR6MAOAMAOBHDAC1HDAC6
SCHEMBL6100637 0.85 HTR6 (0.54) HTR6DRD2HTR7HTR2A
SCHEMBL6097579 0.85 AR (0.47) HTR6MEN1KMT2AAR
SCHEMBL6098330 0.81 L3MBTL1 (0.62) HTR6L3MBTL1DRD2HTR7HTR2A
SCHEMBL6096942 0.81 L3MBTL1 (0.45) HTR6L3MBTL1
SCHEMBL5030687 0.79 KDM4E (0.61) HTR6L3MBTL1HDAC1HDAC6MEN1
SCHEMBL6098592 0.79 PPARD (0.48) MAOAMAOB
SCHEMBL6805163 0.79 HTR6 (0.45) HTR6L3MBTL1
SCHEMBL6098735 0.79 BAZ2B (0.48) HTR6MAOAMAOBMEN1NPC1
SCHEMBL29957300 0.78 HTR6 (0.58) HTR6L3MBTL1HDAC1HDAC6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF HTR6 765/4885L3MBTL1 3650/4885DRD2 930/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF HTR6 883/4885L3MBTL1 3816/4885DRD2 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.